全文获取类型
收费全文 | 8425篇 |
免费 | 596篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 202篇 |
妇产科学 | 61篇 |
基础医学 | 969篇 |
口腔科学 | 196篇 |
临床医学 | 588篇 |
内科学 | 2473篇 |
皮肤病学 | 376篇 |
神经病学 | 435篇 |
特种医学 | 393篇 |
外科学 | 1433篇 |
综合类 | 32篇 |
一般理论 | 1篇 |
预防医学 | 202篇 |
眼科学 | 88篇 |
药学 | 454篇 |
中国医学 | 9篇 |
肿瘤学 | 1113篇 |
出版年
2024年 | 9篇 |
2023年 | 144篇 |
2022年 | 290篇 |
2021年 | 456篇 |
2020年 | 219篇 |
2019年 | 295篇 |
2018年 | 373篇 |
2017年 | 333篇 |
2016年 | 354篇 |
2015年 | 337篇 |
2014年 | 431篇 |
2013年 | 441篇 |
2012年 | 752篇 |
2011年 | 758篇 |
2010年 | 388篇 |
2009年 | 314篇 |
2008年 | 515篇 |
2007年 | 575篇 |
2006年 | 497篇 |
2005年 | 462篇 |
2004年 | 374篇 |
2003年 | 292篇 |
2002年 | 237篇 |
2001年 | 28篇 |
2000年 | 17篇 |
1999年 | 28篇 |
1998年 | 30篇 |
1997年 | 27篇 |
1996年 | 18篇 |
1995年 | 14篇 |
1994年 | 13篇 |
1993年 | 12篇 |
1992年 | 12篇 |
1991年 | 11篇 |
1990年 | 5篇 |
1989年 | 6篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1973年 | 3篇 |
排序方式: 共有9093条查询结果,搜索用时 15 毫秒
21.
22.
23.
Identification of cembratriene-4,6-diol as antitumor-promoting agent from cigarette smoke condensate
Saito Yutaka; Takizawa Haruo; Konishi Sumie; Yoshida Daisuke; Mizusaki Shigenobu 《Carcinogenesis》1985,6(8):1189-1194
Cigarette smoke condensate (CSC) was separated into severalfractions and each was tested for an inhibitory effect on theearly antigen (EA) of Epstein-Barr virus (EBV) which can beinduced by 12-0-tetradecanoylphorbol-13-acetate (TPA) in Rajicells. Two diastereoisomers of 2,7,11-cembratriene-4,6-diol(- and ß-CBT) were isolated from the neutral fractionsof CSC and these showed potent inhibitory effects on the inductionof EBV-EA by TPA. The doses of - and ß-CBT requiredfor 50% inhibition of EBV-EA induction by TPA were 7.7 and 6.7µg/ml, respectively, which are comparable with those ofretinoic acid, a potent inhibitor of induction of epideral ornithinedecarboxylase (ODC) activity and tumor promotion by TPA in mice.Application of - and ß-CBT to mouse skin prior totreatment with TPA inhibited TPA-induced ODC activity. The degreeof inhibition was dependent on the dose and application of 16.5µmol/mouse of - and ß-CBT resulted in a 50 and40% reduction, respectively, of the maximum of the ODC activityinduced as a result of treatment with TPA. In initiation-promotionexperiments, -CBT markedly inhibited the promoting effect ofTPA on skin tumor formation in mice which were initiated with7,12-dimethylbenz[a]anthracene, but ß-CBT was foundto be less effective. Application of 3.3 µmol of -CBT40 min prior to treatment with TPA (1 µg) resulted ina 53% reduction in the number of papillomas per mouse. Our presentdata suggest that EBV-EA inhibition assay using Raji cells iseffective for the first screening of inhibitors of tumor promotion,and provide evidence that CSC contains antitumor-promoting agentsin addition to carcinogenic and tumor-promoting agents alreadyreported. 相似文献
24.
Noriyuki Amano Kazumasa Matsumoto Yuriko Shimizu Marie Nakamura Hideyasu Tsumura Daisuke Ishii Yuichi Sato Masatsugu Iwamura 《Urologic oncology》2021,39(3):196.e1-196.e7
ObjectiveWe sought to identify heterogeneous nuclear ribonucleoprotein A3 (HNRNPA3) expression in bladder cancer and its relationship to clinicopathological findings and prognosis.MethodsImmunohistochemical staining for HNRNPA3 was performed on 122 archived radical cystectomy specimens, with immunoreactivity being stratified on a 0 to 3 scale. The percentage of HNRNPA3 expressing tumor cells was calculated and multiplied by the staining score over an average of 5 areas to obtain a semiquantitative H-score (maximum value: 300). HNRNPA3 expression was categorized as high (≥80) or low (<80).ResultsThe patients’ median age was 70 years, and the median follow-up period was 39.4 months. High HNRNPA3 expression was significantly associated with lymph node metastasis (P= 0.014) and S100A8, S100A9 and uroplakin III expression (P= 0.028, 0.002, and 0.047, respectively). Log-rank tests indicated that high HNRNPA3 expression was significantly associated with disease progression and cancer-specific death (P= 0.013 and 0.006, respectively). In the Cox proportional hazards regression analysis, only lymph node metastasis was associated with disease progression and cancer-specific survival.ConclusionHNRNPA3 may be a new biomarker to predict biologically aggressive cancers and determine the appropriate treatment modality in patients after radical cystectomy. 相似文献
25.
26.
Tomohiro Kaneko Sakiko Miyazaki Takuma Koike Azusa Murata Ryoko Morimoto Kuniaki Hirose Kazuhisa Takamura Daisuke Endo Atsushi Amano Tohru Minamino 《Internal medicine (Tokyo, Japan)》2022,61(9):1367
Atypical Shone''s complex is a rare congenital anomaly involving a left-sided obstructive lesion of two or three cardiovascular levels. A 70-year-old man with dyspnea on exertion was diagnosed with severe aortic stenosis (AS) with a bicuspid valve, complicated by severe aortic coarctation (CoA) and a double-orifice mitral valve. He underwent surgery for AS and CoA in one session. It is important to search for complicated malformations, even in cases of bicuspid aortic valve found in old age. 相似文献
27.
Daisuke Suzuki Yoshihiro Suzuki Daisuke Sato Kenji Kikuchi Naoki Kanauchi Akiko Nishida Yasuyuki Ohta 《Internal medicine (Tokyo, Japan)》2022,61(9):1443
Anti-voltage-gated potassium channel complex antibodies-mediated disorder includes Isaacs'' syndrome, which is characterized by neuromyotonia, and Morvan syndrome, which is characterized by neuromyotonia, encephalopathy and autonomic dysfunction. We herein report a patient with Morvan syndrome that converted from Isaacs'' syndrome after thymectomy. The patient first presented with myospasm in all extremities and positivity for both anti-leucine-rich glioma inactivated 1 (LGI1) and anti-contactin-associated protein like 2 (CASPR2) antibodies and subsequently developed encephalopathy after thymectomy, which was successfully improved by immunotherapy. This is the first case of Morvan syndrome wherein thymectomy worsened Isaacs'' syndrome, suggesting that immunotherapy should be considered for Isaacs'' syndrome accompanied by positivity for both anti-LGI1 and anti-CASPR2 antibodies to prevent worsening to Morvan syndrome. 相似文献
28.
Yuraporn Sahasakul Wannee Angkhasirisap Aroonwan Lam-ubol Amornrat Aursalung Daisuke Sano Kentaro Takada Dunyaporn Trachootham 《Nutrients》2022,14(10)
Many types of cancer have metabolic alterations with increased glycolysis. Identification of alternative sweeteners that do not fuel cancer is a novel approach to cancer control. The present study aimed to investigate the effects of xylitol on tumor growth and survival of mice bearing orthotopic xenograft of tongue cancers. The results showed that partial substitution of glucose with xylitol (glucose 0.35 g plus xylitol 2.06 g/kg body weight) non-significantly reduced tumor volume, and significantly prolonged the median survival time from 19 days in the control to 30.5 days in the xylitol group. Immunohistochemical data of the tongue tissue shows significantly lower intense-to-mild staining ratios of the proliferation marker Ki-67 in the xylitol than those of the control group (p = 0.04). Furthermore, the xylitol substitution significantly reduced the expression of the rate-limiting glycolytic enzyme, phosphofructokinase-1 (PFK-1) (p = 0.03), and showed a non-significant inhibition of PFK activity. In summary, partial substitution of glucose with xylitol at the equivalent dose to human household use of 10 g/day slows down tumor proliferation and prolongs survival of mice bearing an orthotopic oral cancer xenograft, possibly through glycolytic inhibition, with minimal adverse events. The insight warrants clinical studies to confirm xylitol as a candidate sweetener in food products for cancer survivors. 相似文献
29.
30.
Daisuke Tamanoi Koichi Saruwatari Kosuke Imamura Ryo Sato Takuya Jodai Shohei Hamada Yusuke Tomita Sho Saeki Shikiko Ueno Yuji Yonemura Hidenori Ichiyasu Takuro Sakagami 《Internal medicine (Tokyo, Japan)》2022,61(11):1731
The effect of radiotherapy during immunotherapy on immune-related adverse events (irAEs) is not fully understood. We herein report a 74-year-old woman diagnosed with lung adenocarcinoma with programmed death ligand 1 expression ≥50% and treated with pembrolizumab. She developed fatal immune thrombocytopenia associated with pembrolizumab immediately following radiotherapy. A flow cytometry analysis of peripheral blood detected an increased expression of programmed death-1 (PD-1) and Ki-67 in CD4+ and CD8+ T cells after radiotherapy, compared with pre-irradiation measurements. This case suggests that radiotherapy may evoke irAEs during treatment with anti-PD-1 antibodies, which physicians should consider when using radiotherapy in patients treated with these drugs. 相似文献